Acute renal failure occurs frequently in hospitalized patients and is associated with significant morbidity and mortality. An effort to better understand the epidemiology and pathophysiology of this disease will hopefully lead to improvement in patient outcomes. Considerable effort has been expended to develop techniques to prevent acute renal failure or to facilitate its resolution. In this review we attempt to summarize some of these recent advances.
Introduction
Acute renal failure (ARF) is generally defined as an abrupt and sustained decline in the glomerular filtration rate (GFR) [1] , which leads to accumulation of nitrogenous waste products and uremic toxins. Incidence of ARF varies from 5 to 15% in critically ill patients [2] . Although the mortality rate of an isolated episode of ARF is approximately 10-15% [3], when ARF occurs in association with multiple organ dysfunction, mortality rates are much higher and vary in published series between 50 and 90%. Many new drugs to prevent and slow the progression of ARF have been studied. However, to date no drug has been convincingly shown to improve the clinical outcomes from ARF. Efforts to understand how to best provide renal replacement therapy (RRT) and explore newer techniques of RRT are currently under way in an effort to favorably alter the outcomes from ARF. In this review, we have summarized some of the latest advances that have been made in this field and touch briefly on therapies that remain on the horizon.
Acute renal failure: definition and outcomes
There has been wide variation in the reported incidence and associated mortality of ARF. This has been partly due to the use of a wide variety of ARF definitions by different investigators. Until recently, no standard definition for acute renal dysfunction (ARD) existed. Although many definitions have been used in clinical trials, the association between ARF and milder forms of renal impairment has not been well characterized. Controversy exists as to what functions of the kidney should be assessed, what markers should be used to define ARF and how different degrees of renal dysfunction should be described and quantified. Hence, in an effort to encompass the entire range of acute abnormalities in renal function, the term ARD was used by the Acute Dialysis Quality Initiative group, an international, interdisciplinary collaboration (http://www.adqi.net). This group has also formulated the RIFLE classification to establish a standard definition of ARD [4 ]. The acronym RIFLE defines three grades of increasing severity of ARD (risk, injury, and failure, respectively R, I, and F), and two outcome variables (loss, and end-stage kidney disease, L and E). A unique feature of the RIFLE classification is that it provides for three grades of severity of ARD based on changes in GFR or urine output from the baseline condition (Table 1) . Although this classification makes good physiological and clinical sense, its clinical validity needs to be confirmed. Several efforts are currently under way to do just that.
There is now clear evidence that ARF carries a significant 'attributable mortality'. Patients developing ARF have a significantly higher mortality rate than those who do not, irrespective of whether they require RRT or not [5] [6] [7] [8] . Given this apparent impact of even 'milder forms' of ARF on mortality, it is important to prevent or hasten the resolution of ARF even when RRT is not employed. However, only a few interventions seem to have any effect on reducing the incidence of ARF by achieving clinically meaningful endpoints.
Prevention and treatment of acute renal failure
For the purposes of this review, we have classified the prevention and treatment of ARF into nondialytic strategies, dialytic strategies and strategies that attempt to enhance renal recovery once ARF has occurred.
Nondialytic strategies
Nondialytic strategies include nonpharmocologic strategies such as fluid hydration and avoidance of nephrotoxins and various pharmcological agents to prevent and treat ARF.
Fluids
Using historical controls, patients treated with fluid resuscitation regimes clearly suggest a beneficial role of fluid hydration in preventing ARF [9, 10] . This is especially very clear in certain subgroups of patients such as those with traumatic rhabdomyolysis [11] . Similar evidence is available for prevention of radio-contrast agents and while these data suggest that hydration is clearly important, the type of fluid that is most protective is still under debate. One recent randomized controlled trial (RCT) found that hydration with 0.9% saline infusion significantly reduced contrast nephropathy compared with 0.45% saline in dextrose hydration (0.7% with 0.9% saline versus 2% with 0.45% saline; P ¼ 0.04) [12] . A smaller, more recent single-center RCT, however, showed that hydration with isotonic sodium bicarbonate decreased the incidence of contrast nephropathy further compared with isotonic sodium chloride hydration (1.7% versus 13.6%; P ¼ 0.02) [13 ] .
Contrast media exposure
One systematic review compared low osmolality contrast media with standard contrast media and showed that low osmolality contrast media was less nephrotoxic but did not influence the development of ARF or need for dialysis [14] . However, one subsequent RCT [15 ] (n ¼ 129 diabetic patients with baseline renal insufficiency) compared nonionic iso-osmolar contrast media (iodixanol) to low-osmolar contrast media (iohexol) in patients undergoing cardiac or vascular angiography and found that iso-osmolar nonionic contrast exposure significantly reduced contrast nephropathy compared with low-osmolar contrast exposure (OR 0.09; 95% CI 0.02-0.4).
Diuretics
Multiple small clinical trials have studied the efficacy of loop diuretics in preventing ARF and have provided conflicting results. Most have been underpowered, nonrandomized or had other methodological limitations. One systematic review that compared fluids alone with diuretics in people at risk for ARF from various causes did not show any benefit from diuretics with regards to incidence of ARF, need for dialysis or mortality [16] . More recently, two larger studies have been published, providing conflicting results. The first was a cohort study of patients with ARF in the intensive care unit (ICU), in which patients were characterized by the use of diuretics on or before the day of renal consultation [17] . In this study, with adjustments for relevant co-variates and propensity scores, diuretic use was associated with significantly increased risk of death or nonrecovery of renal function (OR 1.77; 95% CI 1.14-2.76). Subsequently, a recent multinational, observational study (n ¼ 1743) evaluated the effect of loop diuretics on clinical outcomes [18 ] . The study investigators created three multivariate models to assess the relationship between diuretics and mortality and found that diuretic use was not significantly associated with increased mortality in all the three models (OR for death about 1.2 in all three models). However, no benefit was seen either.
Dopamine and dopamine-receptor agonists
Similar to diuretics, dopamine is not effective in the prevention of ARF. Two systematic reviews [19, 20] concluded that there was no role for dopamine in preventing deterioration of renal function in the ICU. A subsequent large multicenter RCT [21] (n ¼ 328) randomized patients with at least one indication of early renal dysfunction to 'low-dose dopamine' (2 mg/kg/min) or placebo. There was no difference in the peak serum creatinine concentration, ICU/hospital length of stay or need for renal replacement therapy between the groups. Based on these data, we conclude that there is indeed no role for 'low-dose' dopamine in the prevention of ARF from any etiology.
Several small RCTs have shown that fenoldopam increases renal blood flow, renal plasma flow, and creatinine clearance [22] [23] [24] . Based on these physiological data, several clinical trials have been done looking at the role of fenoldopam in preventing ARF. A recent placebocontrolled, multicenter RCT [25 ] randomized 315 patients with baseline creatinine clearance less than 60 ml/min to fenoldopam mesylate or placebo and found no difference between the groups in the incidence of contrast nephropathy. Furthermore, fenoldopam has been shown to cause hypotension and therefore can predispose to ARF by reducing renal perfusion pressure [26] .
Natriuretic peptides
Several RCTs have evaluated the role of atrial natriuretic peptide (anaritide) in the prevention of ARF. The largest RCT done so far [27] randomized 504 patients with early renal dysfunction to placebo or 24 h infusion of anaritide at a dose of 200 ng/kg/min. In this study, there were no differences between the groups in the dialysis-free survival at 21 days (primary end-point), need for dialysis or mortality. However, prospectively defined subgroup analysis suggested that oliguric patients (<400 ml urine/day) had improved dialysis-free survival (P ¼ 0.008) in comparison to the placebo group, while nonoliguric patients had worsened dialysis-free survival with anaritide than control groups (P ¼ 0.03). This worsening in outcome in nonoliguric patients was thought to be due to hypotensive effects of anaritide (46% incidence of hypotension in anaritide group versus 18% in the placebo group). Based on these findings, a subsequent RCT [28] was performed on patients with oliguric ARF using the same dose of anaritide. This study was terminated after interim analysis due to failure to see any benefit with anaritide. However, notably more patients in the anaritide group developed significant hypotension (systolic blood pressures <90 mmHg) compared with the placebo group during the study-drug infusion (95% versus 55%, respectively; P < 0.001).
Recently, one RCT [29] randomized 61 patients post cardiac-surgery requiring bypass with normal preoperative renal function to smaller doses of human recombinant natriuretic peptide (rh-ANP) (50 ng/kg/min) continuous intravenous infusion or placebo when serum creatinine increased by 50% from baseline. In this study, 21% of patients in the rh-ANP group required dialysis by 21 days compared with 47% in patients in the placebo group. This positive study differed significantly from the previous negative studies in that patients included were more homogeneous, a smaller dose of natriuretic peptide was used and infusion duration was longer. However, this study also has several limitations, including small patient population and baseline differences between the two groups. Hence larger studies using this dose in cardiac surgical patients are necessary prior to routine use of this drug for prevention of ARF.
Theophylline
Several small clinical studies have been done to evaluate the role of theophylline, an adenosine antagonist, in the prevention of contrast nephropathy [30] [31] [32] [33] . However, these studies have led to conflicting results. A recent metaanalysis showed that patients who received theophylline had a smaller rise in serum creatinine compared with those who received placebo [34] . This metaanalysis did not examine the incidence of ARF or control for hydration status of patients included in the studies. Furthermore, the clinical relevance and implication of this endpoint remain unclear.
N-Acetylcysteine
Several small RCTs [35] [36] [37] [38] have evaluated the role of N-acetylcysteine (NAC) in the prevention of contrast nephropathy. These studies were all small, differed in the dose and timing of NAC administration and hence provided conflicting results. This has led to three systematic reviews, all of which found that NAC plus hydration reduced contrast nephropathy more compared with hydration alone in people with chronic renal insufficiency [39,40 ,41] . However, a recent study has suggested that NAC could independently decrease serum creatinine without any effect on GFR (as evaluated by other surrogate outcomes such as serum cystatin C levels) [42 ] . Hence the current implications of reduction in serum creatinine after contrast administration with the use of NAC remain unclear. Considering the low cost of NAC and its favorable side-effect profile, however, it may be reasonable to use NAC for the prevention of contrast nephropathy in high-risk patients, at least until further evidence is available.
Dialytic strategies
Although drug therapies have been unsuccessful to date, changes in dialysis, dose, modality and timing, and selection of membranes appear to impact outcome from ARF. Although many questions remain unanswered with regards to many operational factors of renal replacement therapy, such as timing of initiation, modality, dose of dialysis etc., some improvements in the dialysis delivery seem to improve patient outcomes in ARF. An extensive discussion on various operational factors in providing 'adequate dialysis' is beyond the scope of this review. Of these, only three have achieved the level of evidence that warrants specific consideration. First, the use of biocompatible synthetic dialysis membranes instead of cuprophane appears to improve overall outcomes. One metaanalysis concluded that biocompatible membranes reduce mortality [43] . In this study, so-called 'semibiocompatible' cellulosic membranes were statistically indistinguishable from purely synthetic membranes, but there was a clear trend toward worse outcome. Second, high-dose continuous replacement renal therapy appears to be better than lower doses. One RCT [44] found that high-dose versus low-dose continuous hemofiltration significantly reduces mortality (number needed to treat ¼ 7). Similar results were reported in a small study of intermittent hemodialysis [45] , although several concerns have been raised about the validity of the results. Currently, a multi-center RCT is under way in the United States to definitively address this question.
There is no clear consensus as to which, if any, modality of RRT is superior with regards to improving clinical outcomes in ARF. Particularly, the relative roles of intermittent hemodialysis (IHD) and continuous renal replacement therapy (CRRT) in ARF remain debatable. Despite many theoretical advantages to CRRT, evidence supporting its superiority over IHD with regards to mortality or other clinical outcome measures is lacking. Many studies have compared these two modalities, but have been limited by their observational nature or by large differences in baseline characteristics of the patient population [46] . Two metaanalyses have looked to address this issue, but have provided conflicting results [47, 48] . Based on these conflicting results, a recent international consensus conference concluded that no firm overall recommendations for patient selection for CRRT could be made, except in the setting of co-existing intracranial hypertension, where CRRT appears to be superior [49] .
Another aspect of dialytic support that is controversial is that of timing of initiation. This issue has been studied in only a very limited way and most studies have been too small or defined timing in such an imprecise fashion that it is difficult to draw conclusions. One retrospective study [50] , which used serum BUN as a surrogate for 'timing of initiation' of dialysis in ARF showed that patients who were dialyzed earlier in their course of disease (mean BUN 42.6 mg/dl) had a better survival (39% versus 20%) compared with those in whom dialysis was initiated later (mean BUN 94.5 mg/dl). These results were not supported by a recent RCT [51] , however, in which patients were randomized to three groups: early high-volume hemofiltration ( 
Enhancing renal recovery
Improved understanding of pathophysiology of ARF has led to an appreciation of inflammatory mechanisms involved. Importantly, this new paradigm also emphasizes the importance of cellular mechanism of repair, proliferation and re-differentiation. Although several novel therapeutic approaches, targeting specific molecules in pathways leading to ARF, are showing promising results in animal studies, there are currently no convincing human data [52] . Numerous growth factors including insulin-like growth factor, hepatocyte growth factor and vascular endothelial growth factor have important antiapoptotic and proproliferation effects. Although many small clinical trials have evaluated the role of growth factors in the process of renal recovery from ARF [53, 54] , the largest RCT done to date [55] has not shown any benefit with these agents. Finally, newer agents such as bone morphogenic protein-7 and erythropoietin have promising, albeit largely hypothetical, effects on renal tubular cells and may potentially enhance renal recovery [56, 57] . Clinical trials for both of these agents are urgently needed.
Conclusion
ARF afflicts a large fraction of ICU patients and carries high morbidity and mortality. Preventing the development of ARF remains an attractive but difficult proposition. Aggressive fluid hydration, minimizing nephrotoxins and maintaining 'adequate' renal perfusion pressure still remain the mainstay of ARF prevention. Wellpowered studies have failed to demonstrate that drugs such as low-dose dopamine, atrial natriuretic peptide or diuretics can prevent onset or deterioration of renal function in the critically ill. Recently, pooled data from small studies suggest that NAC can reduce the increase in serum creatinine associated with radio-contrast administration. Improved understanding on how to best provide supportive therapy to the kidneys by renal replacement therapy increases the possibility of improving clinical outcomes in the near future. Finally, although insight into mechanisms of renal injury and renal recovery has improved tremendously, no drugs are currently available to enhance or hasten renal recovery once ARF occurs. However, several promising agents are on the horizon.
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